Top

Cancer Causes & Control

Published in:

01-06-2006 | Original Paper

Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States)

Authors: Christopher I. Li, Kathleen E. Malone, Janet R. Daling

Published in: Cancer Causes & Control | Issue 5/2006

Abstract

Objective

To assess interactions between use of estrogen plus progestin hormone therapy (EPHT) and body mass index (BMI) in relation to risks of different types of breast cancer, based on histology and hormone receptor status.

Methods

We conducted a population-based case-control study that compared 975 postmenopausal breast cancer cases to 1,007 controls. Interactions between menopausal hormone therapy (HT) and BMI in relation to risk of different breast cancer types were evaluated using logistic regression.

Results

Obese (BMI ≥30.0 kg/m²) never users of HT had 1.7–fold to 2.3–fold elevated risks of ductal and ER+/PR+ tumors, respectively, compared to thinner women. BMI was not related to breast cancer risk among current HT users. Current EPHT users for ≥5 years had 2.1 to 9.6-fold elevated risks of lobular and ER+/PR+ tumors compared to never users of HT regardless of BMI. Current EPHT users for ≥5 years with a BMI ≤24.9 kg/m²also had a 2.6-fold elevated risk of ductal carcinoma. However, none of the interactions between BMI and HT use evaluated reached statistical significance.

Conclusions

While interactions between HT and BMI are well established, they appear to only be present among certain breast cancer types. Since obesity is related to breast cancer risk only among never users of HT, as HT use declines the relative impact of obesity on breast cancer incidence may grow.

The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

Buist DS, Newton KM, Miglioretti DL, et al. (2004) Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104:1042–1050PubMed

Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE (2004) Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 13:220–224CrossRefPubMed

Friedenreich CM, Courneya KS, Bryant HE (2002) Case-control study of anthropometric measures and breast cancer risk. Int J Cancer 99:445–452CrossRefPubMed

Huang Z, Willett WC, Colditz GA, et al. (1999) Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am J Epidemiol 150:1316–1324PubMed

Lahmann PH, Hoffmann K, Allen N, et al. (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111:762–771CrossRefPubMed

Morimoto LM, White E, Chen Z, et al. (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 13:741–751CrossRefPubMed

Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45:277–282PubMed

10.

Chetkowski RJ, Meldrum DR, Steingold KA, et al. (1986) Biologic effects of transdermal estradiol. N Engl J Med 314:1615–1620PubMed

11.

Colditz GA, Stampfer MJ, Willett WC, et al. (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439CrossRefPubMed

12.

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350: 1047–1059

13.

Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81:339–344CrossRefPubMed

14.

Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. JAMA 283:485–491CrossRefPubMed

15.

Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274: 137–142CrossRefPubMed

16.

Newcomb PA, Longnecker MP, Storer BE, et al. (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142:788–795PubMed

17.

Ursin G, Tseng CC, Paganini-Hill A, et al. (2002) Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 20:699–706CrossRefPubMed

18.

Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741CrossRefPubMed

19.

Daling JR, Malone KE, Doody DR, et al. (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464CrossRefPubMed

20.

Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570–2577PubMed

21.

Li CI, Malone KE, Porter PL, et al. (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254–3263PubMed

22.

Newcomb PA, Titus-Ernstoff L, Egan KM, et al. (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593–600PubMed

23.

Newcomer LM, Newcomb PA, Potter JD, et al. (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225–233CrossRefPubMed

24.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR (2003) Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65–79 years of age. Int J Cancer 107:647–651CrossRefPubMed

25.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRefPubMed

26.

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591CrossRefPubMed

27.

Goodman MT, Nomura AM, Wilkens LR, Kolonel LN (1990) Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 131:815–825PubMed

28.

Jain MG, Rohan TE, Howe GR (1999) Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 10:260–263PubMed

29.

Paganini-Hill A, Ross RK (1982) Reliability of recall of drug usage and other health-related information. Am J Epidemiol 116:114–122PubMed

30.

Persson I, Bergkvist L, Adami HO (1987) Reliability of women’s histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol 16:222–228PubMed

31.

Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92:720–729CrossRefPubMed

32.

Field RW, Smith BJ, Platz CE, et al. (2004) Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 96:1105–1107PubMed

33.

Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424PubMed

34.

Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28–34CrossRefPubMed

35.

Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H (1993) Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer correlation of histopathology and prognostic factors. Ann Surg 218:13–21PubMed

36.

Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049–2058PubMed

Title: Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States)
Authors: Christopher I. Li
Kathleen E. Malone
Janet R. Daling
Publication date: 01-06-2006
Publisher: Kluwer Academic Publishers
Published in: Cancer Causes & Control / Issue 5/2006
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-005-0001-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2006

Patterns of Disparity: Ethnic and Socio-economic Trends in Breast Cancer Mortality in New Zealand

Re: Glaser et al

Frequent Tanning Bed Use, Weight Concerns, and Other Health Risk Behaviors in Adolescent Females (United States)

Maternal Use of Recreational Drugs and Neuroblastoma in Offspring: A Report from the Children’s Oncology Group (United States)

Body Size and Risk of Epithelial Ovarian Cancer (United States)

Cancer and Laterality: A Study of The Five Major Paired Organs (UK)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer